Teleflex Incorporated (FRA:TBH)
Germany · Delayed Price · Currency is EUR | Market Cap | 4.73B -1.4% |
| Revenue (ttm) | 1.97B +110.9% |
| Net Income | -903.03M |
| EPS | -20.49 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 14.54 |
| Dividend | 1.17 (1.07%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | n/a |
| Open | 110.00 |
| Previous Close | 110.20 |
| Day's Range | 110.00 - 110.00 |
| 52-Week Range | 85.00 - 121.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Teleflex
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and col... [Read more]
News
Teleflex’s Arrowg+ard Technology reduces CLABSI risk in peer-reviewed study
Teleflex (TFX) announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters, or CVCs, protected with Arrowg+ard ...
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Jou...
BofA upgrades Teleflex to Buy, says growth potential not appreciated
As previously reported, BofA analyst Travis Steed upgraded Teleflex (TFX) to Buy from Neutral with a price target of $158, up from $145. With a new management team and better…
Teleflex upgraded to Buy from Neutral at BofA
BofA upgraded Teleflex (TFX) to Buy from Neutral with a price target of $158, up from $145.
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective...
Teleflex to showcase Dynetic-35 Stent System at CIRSE 2026
Teleflex (TFX) announced it will showcase technologies at CIRSE 2026 in Copenhagen. Among the featured technologies will be the Dynetic-35 Balloon-Expandable Cobalt Chromium Stent System. This technol...
Teleflex to showcase technologies at CIRSE 2026 in Copenhagen
Teleflex (TFX) Incorporated announced it will showcase technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technol...
Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen,...
Teleflex price target raised to $158 from $145 at UBS
UBS raised the firm’s price target on Teleflex (TFX) to $158 from $145 and keeps a Neutral rating on the shares. The firm updated its model post the Q2 earnings…
Teleflex price target raised to $150 from $143 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Teleflex (TFX) to $150 from $143 and keeps a Hold rating on the shares after its Q2 earnings beat. A…
Teleflex price target raised to $155 from $150 at Raymond James
Raymond James raised the firm’s price target on Teleflex (TFX) to $155 from $150 and keeps an Outperform rating on the shares. Teleflex delivered solid Q2 results, raised EPS guidance,…
Teleflex Earnings Call Transcript: Q2 2026
Q2 saw strong Vascular and Surgical growth, offset by Interventional integration delays, leading to lowered revenue guidance but higher EPS outlook. Strategic divestitures and capital returns are progressing, with innovation milestones achieved. 2026 is a transition year, with significant improvement expected in 2027.
Teleflex Earnings release: Q2 2026
Teleflex released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Teleflex Slides: Q2 2026
Teleflex has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Teleflex Quarterly report: Q2 2026
Teleflex has published its Q2 2026 quarterly earnings report on August 6, 2026.
Teleflex raises 2026 adjusted EPS view 6.90-$7.20 from $6.25-$6.55
2026 EPS consensus $6.67. Lowers 2026 revenue growth view to 13.4%-14.4% from 14.4%-15.4% from 2025 revenue of $1.98B, consensus $2.29B.
Teleflex reports Q2 adjusted EPS $1.76, consensus $1.28
Reports Q2 cont-op revenue $570.3M, consensus $559.57M. “We delivered a strong Q2, led by excellent performance in our Vascular and Surgical businesses, while continuing to take decisive actions to st...
Teleflex Announces Quarterly Dividend
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. Th...
Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2026. Second quarter 2026 continuing operations f...
Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow's MedTech Innovators
Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks...
Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has completed the previously disclosed divestiture of its OEM busin...
Teleflex price target raised to $159 from $147 at Needham
Needham analyst Mike Matson raised the firm’s price target on Teleflex (TFX) to $159 from $147 and keeps a Buy rating on the shares. The company’s EZPLAZ Freeze Dried Plasma,…
Teleflex announces FDA BLA approval of Ezplaz freeze dried plasma
Teleflex (TFX) announced it has received Biologics License Application (BLA) approval for EZPLAZ Freeze Dried Plasma (FDP) from the U.S. Food and Drug Administration (FDA). EZPLAZ FDP is approved for…
Teleflex Announces FDA BLA Approval of EZPLAZ™ Freeze Dried Plasma
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has received Biologics License Application (BLA) approval for EZPL...
FDA grants Teleflex unit license for Ezplaz Freeze Dried Plasma
The Food and Drug Administration said it licensed Ezplaz Freeze Dried Plasma, making it the first freeze-dried plasma product licensed for use in the United States. Ezplaz is intended for…